Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Wellbutrin
|
| gptkbp:brand |
gptkb:Zyban
gptkb:Wellbutrin_SR |
| gptkbp:category |
Category C
|
| gptkbp:class |
aminoketone antidepressant
norepinephrine-dopamine reuptake inhibitor (NDRI) |
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
eating disorders
alcohol withdrawal seizure disorder |
| gptkbp:dosage_form |
100 mg tablet
150 mg once daily 150 mg tablet 200 mg tablet 300 mg maximum daily |
| gptkbp:effective_date |
1996-12-30
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sustained-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Wellbutrin SR
|
| gptkbp:ingredients |
bupropion hydrochloride
|
| gptkbp:interacts_with |
gptkb:drug
antipsychotics other antidepressants monoamine oxidase inhibitors (MAO Is) |
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_used_for |
gptkb:historical_event
seasonal affective disorder |
| gptkbp:lifespan |
21 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
gptkb:bupropion
|
| gptkbp:scholarships |
avoid alcohol
monitor for mood changes consult doctor before use with other medications do not stop abruptly report seizures immediately |
| gptkbp:side_effect |
dizziness
nausea weight loss insomnia dry mouth |